tetano
Editor, Senior Moderator
Sci Rep
. 2024 Mar 4;14(1):5365.
doi: 10.1038/s41598-024-55320-1. Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Lawrence Reiter[SUP] 1 [/SUP], Johann Greffrath[SUP] 2 [/SUP], Bian Zidel[SUP] 3 [/SUP], Mario Ostrowski[SUP] 4 [/SUP], Jennifer Gommerman[SUP] 5 [/SUP], Shabir A Madhi[SUP] 2 [/SUP], Richard Tran[SUP] 1 [/SUP], Natalia Martin-Orozco[SUP] 1 [/SUP], Rajesh Krishnan Gopalakrishna Panicker[SUP] 1 [/SUP], Curtis Cooper[SUP] 6 [/SUP], Aleksandra Pastrak[SUP] 7 [/SUP]
Affiliations
In the aftermath of the COVID-19 pandemic, the evolution of the SARS-CoV-2 into a seasonal pathogen along with the emergence of new variants, underscores the need for dynamic and adaptable responses, emphasizing the importance of sustained vaccination strategies. This observer-blind, double-dummy, randomized immunobridging phase 2 study (NCT05175742) aimed to compare the immunogenicity induced by two doses of 40 μg PTX-COVID19-B vaccine candidate administered 28 days apart, with the response induced by two doses of 30 µg Pfizer-BioNTech COVID-19 vaccine (BNT162b2), administered 21 days apart, in Nucleocapsid-protein seronegative adults 18-64 years of age. Both vaccines were administrated via intramuscular injection in the deltoid muscle. Two weeks after the second dose, the neutralizing antibody (NAb) geometric mean titer ratio and seroconversion rate met the non-inferiority criteria, successfully achieving the primary immunogenicity endpoints of the study. PTX-COVID19-B demonstrated similar safety and tolerability profile to BNT162b2 vaccine. The lowest NAb response was observed in subjects with low-to-undetectable NAb at baseline or no reported breakthrough infection. Conversely, participants who experienced breakthrough infections during the study exhibited higher NAb titers. This study also shows induction of cell-mediated immune (CMI) responses by PTX-COVID19-B. In conclusion, the vaccine candidate PTX-COVID19-B demonstrated favourable safety profile along with immunogenicity similar to the active comparator BNT162b2 vaccine.
. 2024 Mar 4;14(1):5365.
doi: 10.1038/s41598-024-55320-1. Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study
Lawrence Reiter[SUP] 1 [/SUP], Johann Greffrath[SUP] 2 [/SUP], Bian Zidel[SUP] 3 [/SUP], Mario Ostrowski[SUP] 4 [/SUP], Jennifer Gommerman[SUP] 5 [/SUP], Shabir A Madhi[SUP] 2 [/SUP], Richard Tran[SUP] 1 [/SUP], Natalia Martin-Orozco[SUP] 1 [/SUP], Rajesh Krishnan Gopalakrishna Panicker[SUP] 1 [/SUP], Curtis Cooper[SUP] 6 [/SUP], Aleksandra Pastrak[SUP] 7 [/SUP]
Affiliations
- PMID: 38438427
- PMCID: PMC10912344
- DOI: 10.1038/s41598-024-55320-1
In the aftermath of the COVID-19 pandemic, the evolution of the SARS-CoV-2 into a seasonal pathogen along with the emergence of new variants, underscores the need for dynamic and adaptable responses, emphasizing the importance of sustained vaccination strategies. This observer-blind, double-dummy, randomized immunobridging phase 2 study (NCT05175742) aimed to compare the immunogenicity induced by two doses of 40 μg PTX-COVID19-B vaccine candidate administered 28 days apart, with the response induced by two doses of 30 µg Pfizer-BioNTech COVID-19 vaccine (BNT162b2), administered 21 days apart, in Nucleocapsid-protein seronegative adults 18-64 years of age. Both vaccines were administrated via intramuscular injection in the deltoid muscle. Two weeks after the second dose, the neutralizing antibody (NAb) geometric mean titer ratio and seroconversion rate met the non-inferiority criteria, successfully achieving the primary immunogenicity endpoints of the study. PTX-COVID19-B demonstrated similar safety and tolerability profile to BNT162b2 vaccine. The lowest NAb response was observed in subjects with low-to-undetectable NAb at baseline or no reported breakthrough infection. Conversely, participants who experienced breakthrough infections during the study exhibited higher NAb titers. This study also shows induction of cell-mediated immune (CMI) responses by PTX-COVID19-B. In conclusion, the vaccine candidate PTX-COVID19-B demonstrated favourable safety profile along with immunogenicity similar to the active comparator BNT162b2 vaccine.